Search results for "Tissue microarray"

showing 8 items of 48 documents

Tissue microarrays analysis in chondrosarcomas: light microscopy, immunohistochemistry and xenograft study

2008

Abstract Background Chondrosarcoma (Chs) is the third most frequent primary malignant tumour of bone and can be primary or secondary, the latter results mainly from the malignant transformation of a benign pre-existing tumour. Methods All the cases diagnosed as Chs (primary tumours, recurrences and/or metastasis and xenotransplanted Chs) from the files of our Department were collected. Only cases with paraffin blocks available were selected (Total 32 cases). Six Tissue Microarrays (TMAs) were performed and all the cases and biopsies were distributed into the following groups: a) only paraffin block available from primary and/or metastatic tumours (3 TMAs), b) paraffin block available from p…

Pathologymedicine.medical_specialtyTissue microarrayHistologyintegumentary systembusiness.industryCD99General Medicinemedicine.diseaseMalignant transformationStainingMetastasisPathology and Forensic MedicineProceedingshemic and lymphatic diseasesSurvivinlcsh:PathologymedicineImmunohistochemistryChondrosarcomabusinessskin and connective tissue diseaseslcsh:RB1-214Diagnostic Pathology
researchProduct

Differential Gene Expression of Medullary Thyroid Carcinoma Reveals Specific Markers Associated with Genetic Conditions

2013

Maliszewska, Agnieszka et al.

Pathologymedicine.medical_specialtyendocrine system diseasesInheritance PatternsMultiple endocrine neoplasia type 2ApoptosisBiologyGermlinePathology and Forensic MedicineThyroid carcinomaAntigens CDCell Line TumormedicineBiomarkers TumorGene silencingCluster AnalysisHumansGenetic Predisposition to DiseaseAC133 AntigenGene SilencingThyroid NeoplasmsRNA Small InterferingGlycoproteinsRegulation of gene expressionTissue microarrayReverse Transcriptase Polymerase Chain ReactionGene Expression ProfilingWnt signaling pathwaymedicine.diseaseImmunohistochemistryCarcinoma NeuroendocrineGene expression profilingGene Expression Regulation NeoplasticGene Knockdown TechniquesCancer researchPeptides
researchProduct

Systematic Comparative Protein Expression Profiling of Clear Cell Renal Cell Carcinoma

2009

Proteome-based technologies represent powerful tools for the analysis of protein expression profiles, including the identification of potential cancer candidate biomarkers. Thus, here we provide a comprehensive protein expression map for clear cell renal cell carcinoma established by systematic comparative two-dimensional gel electrophoresis-based protein expression profiling of 16 paired tissue systems comprising clear cell renal cell carcinoma lesions and corresponding tumor-adjacent renal epithelium using overlapping narrow pH gradients. This approach led to the mapping of 348 distinct spots corresponding to 248 different protein identities. By implementing restriction criteria concernin…

Regulation of gene expressionGel electrophoresisTwo-dimensional gel electrophoresisTissue microarrayBiologymedicine.diseaseProteomicsBiochemistryMolecular biologyAnalytical ChemistryClear cell renal cell carcinomaProteomemedicineFatty Acid Binding Protein 3Molecular BiologyMolecular & Cellular Proteomics
researchProduct

Splenic Marginal Zone Lymphoma Shows a Distinct Pattern of DNA Copy Number Aberrations That Correlates with Tumor Characteristics and Predicts Diseas…

2006

Abstract Splenic marginal zone lymphoma (SMZL) is an indolent B cell malignancy whose diagnosis is based on lymphocyte morphology, immunophenotype and marrow and/or splenic histology. Unlike other lymphomas, there is not a common chromosomal translocation specific for SMZL, and genetic prognostic factors are poorly defined. To investigate the pattern of genomic aberrations in SMZL, we applied comparative genomic hybridization to BAC microarrays (array CGH) to a well characterized series of 75 SMZL specimens. We applied two different 1 Mb-resolution BAC arrays: UCSF HumArray 3.2 and a novel array CGH platform developed at Univ. of Salamanca. These arrays allowed us to detect DNA copy number …

Tissue microarrayImmunologyFollicular lymphomaCell BiologyHematologyBiologymedicine.diseaseBiochemistryMolecular biologyLymphomaImmunophenotypingComplex KaryotypemedicineMantle cell lymphomaSplenic marginal zone lymphomaComparative genomic hybridizationBlood
researchProduct

Infrequent promoter methylation of the MGMT gene in liver metastases from uveal melanoma.

2008

Uveal melanoma is associated with a high mortality rate once metastases occur, with over >90% of metastatic patients dying within less than 1 year from metastases to the liver. The intraarterial hepatic (iah) administration of the alkylating agent fotemustine holds some promise with response rates of 36% and median survival of 15 months. Here, we investigated whether the DNA-repair-protein MGMT may be involved in the variability of response to fotemustine and temozolomide in uveal melanoma. Epigenetic inactivation of MGMT has been demonstrated to be a predictive marker for benefit from alkylating agent therapy in glioblastoma. We found a methylated MGMT promoter in 6% of liver metastases fr…

Uveal NeoplasmsCancer ResearchPathologymedicine.medical_specialtyProtein Array AnalysisAntineoplastic AgentsBiologyMetastasischemistry.chemical_compoundPredictive Value of TestsmedicineBiomarkers TumorHumansPromoter Regions GeneticneoplasmsDNA Modification MethylasesMelanomaTemozolomidePredictive markerTissue microarrayMelanomaTumor Suppressor ProteinsLiver NeoplasmsCancerDNA Methylationmedicine.diseaseImmunohistochemistrydigestive system diseasesNitrogen mustardDNA Repair EnzymesOncologychemistryCancer researchFotemustinemedicine.drugInternational journal of cancer
researchProduct

Tissue microarray technology in breast cancer subtyping

2008

breast cancerrintasyöpätissue microarray technologyimmunohistochemistrybreast carcinomacancer marker
researchProduct

Prognostic value of partial genetic instability in neuroblastoma with ≤50% neuroblastic cell content

2011

Piqueras M, Navarro S, Canete A, Castel V & Noguera R (2011) Histopathology59, 22–30 Prognostic value of partial genetic instability in neuroblastoma with ≤50% neuroblastic cell content Aims:  Better understanding of neuroblastoma genetics will improve with genome-wide techniques. However, performing these analyses in samples with <60% neuroblast cells is not adequate. We evaluated the utility of fluorescence in situ hybridization (FISH) on tissue microarrays (TMA) in detecting partial genetic instability (PGI), focusing on samples with ≤50% neuroblast cells. Methods and results:  Alterations of 11q and 17q were detected by FISH on 369 neuroblastoma samples in TMA. Status of the MYCN gene a…

medicine.medical_specialtyPathologyHistologyTissue microarraymedicine.diagnostic_testCellCancerAnatomical pathologyGeneral MedicineBiologymedicine.diseasePathology and Forensic Medicinemedicine.anatomical_structureNeuroblastGenetic markerNeuroblastomamedicinelipids (amino acids peptides and proteins)Fluorescence in situ hybridizationHistopathology
researchProduct

Prevalence and Clinical Outcomes for Patients With ALK Gene Rearrangement in Europe: Preliminary Results from the European Thoracic Oncology Platform…

2012

ABSTRACT Background The prevalence of ALK gene rearrangement (ALK+) in European patients with non-small cell lung cancer (NSCLC) is unknown. The Lungscape project provides a platform to evaluate its expression and clinical significance in a large cohort of patients with resected NSCLC from 13 European sites in 11 countries. Methods Participating sites retrospectively identified cases of NSCLC with clinical demographic and outcome data, and available tissue for research according to predefined protocol criteria. Local ethical and regulatory approvals were adhered to. Clinical data were entered to a central, secure database. Accepted cases on the basis of completeness of clinical data were as…

medicine.medical_specialtyTissue microarrayClinical pathologyALK Gene Rearrangementbusiness.industryHematologymedicine.diseaseOncologyInternal medicineThoracic OncologyCohortmedicineAdenocarcinomaImmunohistochemistryClinical significancebusinessAnnals of Oncology
researchProduct